BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative ...
Nasdaq

BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer

Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases "Bob is an important addition to our expanding ...
Seeking Alpha

BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025

NEW YORK, May 7, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will ...

BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative ...
Nasdaq

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

NEW YORK, June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the ...
Seeking Alpha

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

NEW YORK, Feb. 23, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has ...
MedCity News

BrainStorm’s ALS Data Fail to Persuade FDA Advisors, Who Vote Down the Stem Cell Therapy

BrainStorm Cell Therapeutics got the FDA advisory committee meeting it asked for but not the outcome it wanted. After a full day of presentations and testimonials, the panel of outside experts on ...
Yahoo

FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy (Sept 25)

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Signage is seen outside of FDA headquarters in White Oak, Maryland (Reuters) - (This Sept. 25 story has been corrected ...
MedCity News

BrainStorm Cuts 30% of Staff to Refocus on ALS Cell Therapy’s New Phase 3 Trial

BrainStorm Cell Therapeutics is mapping out the path forward for its experimental amyotrophic lateral sclerosis (ALS) therapy, and while those plans include a new Phase 3 clinical trial, the biotech ...
MM&M

BrainStorm Cell stock sinks following negative FDA adcomm vote on ALS drug

An advisory committee to the Food and Drug Administration voted that BrainStorm Cell Therapeutics’ drug for treating amyotrophic lateral sclerosis (ALS) did not demonstrate substantial evidence of ...
Benzinga.com

Why Is Neurodegenerative Disease-Focused Brainstorm Cell Therapeutics Stock Plunging Today?

Brainstorm Cell Therapeutics Inc BCLI shares are sinking after the FDA released briefing documents ahead of the adcomm meeting scheduled on 27 September. PDUFA action date is targeted to occur by 8 ...
Morningstar

Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market

NEW YORK, Feb. 20, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered ...